Job Postings - Ontario
Published: Fri Apr 29, 2011 Updated:Fri Feb 3, 2012*New* from The Algoma District Cancer Program (posted February 3rd, 2012)
For a list of job opportunities available through the CMA click here
- Home
- Networking
- Information
- Breast
- Latest Oncology Updates
- Key Journal Articles
- Prevention
- Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
- Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
- Screening
- Pregnancy
- Metastatic Chemo
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
- First-line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
- Extending Survival with Chemotherapy in Metastatic Breast Cancer
- A systematic review of taxane-containing regimens for metastatic breast cancer
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
- Adjuvant Chemo
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
- Breast-Cancer Adjuvant Therapy with Zoledronic Acid
- Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
- Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open label, phase III, randomised controlled trial
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
- Her2 and Response to Paclitaxel in Node Positive Breast Cancer
- Current Concepts: Local Therapy and Survival in Breast Cancer
- Meta-analysis of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview
- Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
- HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
- Adjuvant Therapy for Breast Cancer in Older Women
- Adjuvant Chemotherapy for Patients With Estrogen Receptor--Positive Breast Cancer
- Selection of Adjuvant Chemotherapy for Treatment of Node-positive Breast Cancer
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
- Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
- Neoadjuvant
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer
- New results from the use of bisphosphonates in cancer patients
- Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902
- Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial
- The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis
- Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
- Neoadjuvant endocrine therapy in breast cancer
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
- Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Updat
- Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
- Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
- Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
- Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
- Bisphosphonates
- Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial
- Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
- Targeted Agents
- Treatment of Metastatic ErbB2-positive Breast Cancer: Options After Progression On Trastuzumab
- Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
- Bevacizumab for Advanced Breast Cancer
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- Management of HER2-Positive Breast Cancer
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
- Herceptin and the Heart -- A Molecular Modifier of Cardiac Failure
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Surgery
- Case 35-2005 — A 56-Year-Old Woman with Breast Cancer and Isolated Tumor Cells in a Sentinel Lymph Node
- Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave- Roussy Breast Cancer Group
- Reanalysis and Results after 12 Years of Follow-Up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer
- Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute
- DCIS
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS *New*
- Medical Progress: Ductal Carcinoma in Situ of the Breast
- Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
- Endocrine
- Zoledronic Acid in the Treatment of Early-Stage Breast Cancer: Is There a Final Verdict?
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES) - submitted on behalf of the IES Investigators
- BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
- Disease Related Outcome with Long Term Follow-up: An Updated Analysis of the Intergroup Exemestane Study (IES)
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
- Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada
- Breast Cancer Adjuvant Endocrine Therapy
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
- Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
- Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-year Survival: an overview of the randomised trials
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
- HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
- Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer
- Anastrozole Alone or in Combination with Tamoxifen Versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: first results of the ATAC randomised trial
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial
- Genetics
- Follow Up
- Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
- Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics
- Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial
- Follow-up care of patients treated for breast cancer: a structured review
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology
- Prevention
- Continuing Medical Education Activities
- Lung
- Latest Oncology Updates
- Key Journal Articles
- Early Stage
- Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
- A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
- Metastatic Chemo
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
- Concurrent chemo and radiation therapy improves long-term survival for inoperable stage III lung cancer
- Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
- Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
- Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
- Phase II Clinical Trial of Chemotherapy-Naïve Patients 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
- Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
- Early Stage
- Multimedia
- Continuing Medical Education Activities
- GI
- Latest Oncology Updates
- Key Journal Articles
- Colon Adjuvant
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer: A Systematic Review and Meta-analysis
- XELOXA Study: Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- MOSAIC Study: Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer
- Rectal Adjuvant
- ACCORD Study: Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
- Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
- Is Preoperative Chemoradiotherapy Still the Treatment of Choice for Rectal Cancer?
- Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
- Colorectal - Metastatic - Chemotherapy
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial
- Intermittent versus continuous oxaliplatin and fl uoropyrimidine combination chemotherapy for fi rst-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
- Colorectal Metastatic - EGFR
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies.
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- The CRYSTAL Study: Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- The PRIME Study: Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer
- The CRYSTAL Study: Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- The OPUS Study: Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- Colorectal - Metastatic - anti VEGF/Double Biologics
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
- Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Gastric
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- AVAGAST Study: Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer- A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- TOGA Study: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
- Pancreatic - Adjuvant
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
- Pancreatic - Metastatic
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- Colon Adjuvant
- Multimedia
- Continuing Medical Education Activities
- GU
- Latest Oncology Updates
- Guidelines
- Key Journal Articles
- Germ Cell - Stage I NSGCT
- Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors
- Randomized Trial of Two or Five Computed Tomography Scans in the Surveillance of Patients With Stage I Nonseminomatous Germ Cell Tumors of the Testis
- Germ Cell - Metastatic
- Germ Cell - Post Chemotherapy Surgery
- Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients With Disseminated Nonseminomatous Germ Cell Tumors: Is a Postchemotherapy Retroperitoneal Lymph Node Dissection Needed After Complete Remission?
- Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery
- Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy (Editorial)
- Germ Cell - Relapsed GCT
- Germ Cell - PET Scan Imaging
- 2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial *New*
- 18Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients with High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22 - The NCRI Testis Tumour Clinical Study Group
- Renal Cell - Targeted Therapy First Line
- Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease
- Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial
- Temsirolimus, Interferon-α, or Both for Advanced Renal-Cell Carcinoma
- Sunitinib versus Interferon-α in Metastatic Renal-Cell Carcinoma
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- Targeted Therapy for Metastatic Renal Cell Carcinoma
- Renal Cell - Cytoreductive Nephrectomy
- Renal Cell - Bisphosphonates
- Renal Cell - Immunotherapy
- Medroxyprogesterone, Interferon alfa-2a, Interleukin 2, or Combination of Both Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis: Results of a Randomized Controlled Trial (The PERCY QUATTRO Trial)
- Systemic therapy for renal cell
- Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial
- Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
- Renal Cell - Bone Targeted Therapy
- Bladder - Chemotherapy in Metastatic Disease
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy
- Bladder - Adjuvant Chemotherapy
- Bladder - Neoadjuvant Chemotherapy
- Prostate - Bone Targeted Therapies
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
- Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
- Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma
- Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- Prostate Cancer Biomarkers: Research Updates at AUA Annual Meeting
- Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Read a review of this article by Dr. Lori Wood
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
- Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men with Metastatic Prostate Cancer
- A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial)
- Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate versus Mitoxantrone/Prednisone and Placebo in Patients with Hormone-Refractory Prostate Cancer and Pain
- Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go?
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma
- Should Bisphosphonates be Used Routinely in Patients with Prostate Cancer metastatic to Bone?
- Prostate - Chemotherapy in Metastatic Disease
- Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
- Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared with Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report from the ASCENT Investigators
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
- Prostate - Immunotherapy in Metastatic Disease
- Prostate - Secondary Hormonal Manipulation
- Antiandrogen Withdrawal Alone or in Combination with Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)
- Flutamide Versus Prednisone in Patients With Prostate Cancer Symptomatically Progressing After Androgen-Ablative Therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary Group
- Prostate - Systemic Therapy Post Docetaxel in a Metastatic Setting
- Prostate Cancer: Evolution or Revolution?
- Abiraterone and Increased Survival in Metastatic Prostate Cancer Read a review of this article by Dr. Lori Wood
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial Read a review of this article by Dr. Lori Wood
- Prostate - Other Articles
- Germ Cell - Stage I NSGCT
- Continuing Medical Education Activities
- Multimedia
- Head & Neck
- Latest Oncology Updates
- Key Journal Articles
- Podcast: ESMO 2011 Interview with Dr Camilla Hoff on the influence of smoking in patients with squamous cell carcinoma of the head and neck
- Early Trial Supports Bevacizumab in Head and Neck Cancer
- Thyroid cancer patients’ involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study
- Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
- The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease
- Clinical significance of micrometastases in lymph nodes from laryngeal squamous cell carcinoma
- Exploring novel therapeutic strategies for cetuximab in head and neck squamous cell carcinoma
- New Guidelines for Reirradiation of Head and Neck Cancer
- Podcast: ESMO 2011 Interview with Professor Jan Vermorken analyzing the results of the phase III SPECTRUM trial
- HPV and Head and Neck Cancer
- Acute-phase response reactants as objective biomarkers of radiation-induced mucositis in head and neck cancer
- Anti-EGFR–targeting agents in recurrent or metastatic head and neck carcinoma: A meta-analysis
- Circulating Tumor Cell Assay Shows Potential for Predicting Prognosis in Head and Neck Carcinoma
- Population-Based Study of Competing Mortality in Head and Neck Cancer
- Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma
- Does PEG Use Cause Dysphagia in Head and Neck Cancer Patients?
- Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer Article Review by Dr Snow
- Increase in stroke risk in patients with head and neck cancer: a retrospective cohort study
- Radiotherapy plus Cetuximab for Squamous- Cell Carcinoma of the Head and Neck
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
- A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy
- Multimedia
- Hematology
- Palliative Care
- Other Tumor Sites
- Supportive Care
- Teaching Cases
- Breast
- Conferences
- In The Clinic
- Multimedia
- Contact
- rss-feed
